VSTS ALERT: Levi & Korsinsky Files Securities Fraud Class Action Against Vestis Corporation - August 8, 2025 Deadline
https://zlk.com/pslra-1/vestis-corporation-lawsuit-submission-form?prid=157697&wire=5&utm_campaign=26
or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.
Cannot view this video? Visit:
https://www.youtube.com/watch?v=UdFDFHiOSqk
THE LAWSUIT: A class action securities lawsuit was filed against Vestis Corporation that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between May 2, 2024 and May 6, 2025.
CASE DETAILS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Vestis' ability to grow its business; notably that Vestis would be unable to execute on planned strategic initiatives to drive purported improvements to the customer experience and its onboarding efforts in order to drive new customer growth, increased customer retention, and increased revenue from existing customers.
On May 7, 2025, Vestis announced its financial results for the second quarter of fiscal 2025, withdrew its revenue and growth guidance for the full fiscal year 2025, and provided guidance for the third quarter of fiscal 2025 that fell significantly below market expectations. The Company attributed its poor results partially to "lost business in excess of new business," but primarily on "lower adds over stops, which is how we describe volume changes with our existing customers." The Company attributed its decision to pull full-year guidance and provide disappointing third quarter targets to the "increasingly uncertain macro environment."
Following this news, the price of Vestis' common stock declined dramatically. From a closing market price of $8.71 per share on May 6, 2025, Vestis' stock price fell to $5.44 per share on May 7, 2025, a decline of about 37.54% in the span of just a single day.
WHAT'S NEXT? If you suffered a loss in Vestis stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslra-1/vestis-corporation-lawsuit-submission-form?prid=157697&wire=5&utm_campaign=26 to learn about your rights to seek a recovery. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/259681
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
12 minutes ago
- Globe and Mail
Why Globe Life Stock Was a Winner Today
Key Points An analyst upgraded her recommendation on the stock. She now feels it's a buy. 10 stocks we like better than Globe Life › Insurance conglomerate Globe Life (NYSE: GL) was a safe bet of a stock on Friday, as investors snapped it up following a bullish analyst move. With that tailwind at its back, Globe Life closed the day nearly 3% higher in price, easily beating the 0.4% increase of the S&P 500 index. CFRA now feels the stock is a buy That move was made by CFRA analyst Catherine Seifert, who upgraded her Globe Life recommendation to buy from her previous hold. She accompanied this with a significant price-target increase to $155 per share from the preceding $130. According to reports, Seifert's change was due to two recent developments -- the second-quarter results Globe Life posted on Wednesday and the resolution of a Securities and Exchange Commission (SEC) investigation. The probe, which concluded on Thursday with the SEC electing not to recommend enforcement action against the company, concerned allegations from short seller reports alleging fraud at both the company and its subsidiary, American Income Life. As for the Q2 earnings, the analyst was cheered by management providing encouraging guidance on anticipated reserve releases in its current Q3 and in the following frame. She also waxed optimistic about the development of underwriting in certain categories, such as mortality. A solid second quarter Those earnings, published on Wednesday, were encouraging in many respects. Globe Life managed to boost its revenue by nearly 3% year over year to $1.48 billion. Although net income was down slightly (by 2%), it beat the consensus analyst estimate. Put another way, it's business as usual for the insurer, and in that rather conservative industry, that's a heartening development. Should you invest $1,000 in Globe Life right now? Before you buy stock in Globe Life, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Globe Life wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,774!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,942!* Now, it's worth noting Stock Advisor's total average return is 1,040% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025
Globe and Mail
12 minutes ago
- Globe and Mail
Why Curaleaf Stock Surged 13% Higher Today
Key Points A letter sent by a clutch of attorneys general to congressional leaders made a case for banking reform for the marijuana industry. Lack of access to basic financial services has been quite a hindrance for the business. 10 stocks we like better than Curaleaf › A new political push for marijuana law reform had an intoxicating effect on Curaleaf (OTC: CURLF) stock as the trading week came to an end. On Friday, the multi-state operator (MSO) was quite the buzzy title on the exchange, with investors boosting its share price by 13% on the day. That compared quite favorably to the minor (0.4%) gain of the S&P 500 (SNPINDEX: ^GSPC) at market close. Banking on change Late on Thursday, a group of 32 attorneys general from U.S. states and territories sent a letter to congressional leaders imploring them to pass a marijuana banking bill. The Secure and Fair Enforcement Regulation (SAFER) Banking Act would allow cannabis businesses to access basic financial services; as the drug is illegal at the federal (if not necessarily the state) level, they are currently barred from these. Many are consequently forced to operate on a cash-only basis, which increases the risks of crime. In the letter, the attorneys general wrote, "As more states continue to consider and implement legalization efforts, the lack of access to America's financial system by cannabis businesses -- which is a direct result of federal banking law -- presents a considerable safety issue for the public." Democrats and Republicans alike Reflecting the broad support marijuana legalization enjoys among the general American public, the 32 attorneys general -- from locales such as Maryland; Washington, D.C.; and Georgia -- are a bipartisan group. While it remains to be seen what, if any, effect their letter has on the rather slow-moving Congressional pot reform efforts, it's good for the weed industry that there continues to be pressure for change. Should you invest $1,000 in Curaleaf right now? Before you buy stock in Curaleaf, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Curaleaf wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,774!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,942!* Now, it's worth noting Stock Advisor's total average return is 1,040% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025
CTV News
12 minutes ago
- CTV News
CTV National News: Are tariffs an unavoidable reality for Canada?
Watch U.S. President Trump says he has not been focused on reaching a final trade deal with Canada. Abigail Bimman on what that might mean for the economy.
